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Abstract
The economic and social burden associated with Chagas disease morbidity and mortality 
is regrettably large in Latin America causing more deaths than does any other parasitic 
disease. Inflammatory dilated cardiomyopathy is, by far, the most important clinical 
consequence of Trypanosoma cruzi infection. The insidious persistence of this parasite 
determines chronic myocarditis progression. The clinical outcome is multifactorial and 
depends on the particular parasite strain and virulence factors, the infective load and 
route of infection, the parasite ability to by-pass the protective immune response, the 
intensity and type of immune response during the acute infective phase, and the host 
genetic background. From the immunological viewpoint, host control of T. cruzi has been 
shown to depend on both humoral and cell-mediated adaptive responses and from the 
innate immune system. In this review, we discuss the most relevant literature conveying 
information on the relevance of identifying a subset of systemic inflammatory molecules 
as potential markers of cardiovascular risk morbidity and mortality in patients with 
Chagas disease. Concurrently, a direct role for the parasite in the perpetuation of myo-
cardial inflammation is substantiated. Ultimately, host-parasite interactions determine 
the course of the ongoing systemic inflammation and the perpetuation of myocardial 
inflammation in genetically predisposed patients.
Keywords: Chagas disease, myocarditis, cardiomyopathy, inflammation, immune 
system, cardiovascular risk
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1. Introduction
Chagas disease is a parasitic disease caused by the Trypanosoma cruzi that affects over 12 million 
people in Central and South America, causing more deaths than any other disease of its kind. 
Large migrations of infected people from the endemic areas are usually observed mainly in 
the United States of America and Europe. The most frequent cardiac complications of chronic 
Chagas disease are left ventricular dilation and dysfunction, aneurysm, congestive heart failure, 
thromboembolism, ventricular arrhythmias, and sudden cardiac death. Chagas disease diagno-
sis is based on serology, namely immunopositivity for immunoglobulin G antibodies to T. cruzi.
Inflammatory dilated cardiomyopathy is, by far, the most important clinical consequence of 
T. cruzi infection. The chronic chagasic cardiomyopathy (CCC) is roughly progressive, and its 
treatment does not differ from that of any other non-chagasic cardiomyopathy in the absence 
of strong evidence. Clinical symptoms usually include dyspnea, palpitations, precordial pain, 
syncope and eventually, sudden death.
Epidemiological data show high mortality and morbidity resulting from the cardiovascular 
disease in chagasic patients. However, there are no hints to suspect cardiovascular risk in 
the silent period of the disease (asymptomatic form). Noticeably, inflammatory factors are 
upraised during the silent period of the Chagas disease. Like atherogenesis, immune-inflam-
matory-mediated effector mechanisms commanded by Th1/Th17 cells are involved in the 
pathophysiology of Chagas disease, having a similar histological hallmark which includes 
Th1/Th17 cells, macrophages, and a characteristic cytokine profile.
Host control of the T. cruzi appears to depend on both humoral and cell-mediated adap-
tive responses, and on the innate immune system as well [1]. The cytokines strongly activate 
multiple functions relevant to cardiovascular homeostasis. According to the literature on the 
subject, there is robust evidence of a systemic upraised level of inflammatory mediators in 
patients with Chagas disease suggesting that the interplay between the parasite aggressive-
ness and the host immune response might have a key role in the perpetuation of myocardial 
inflammation.
The role of the parasitemia is more controversial associated with immunosuppression, dis-
ease reactivation, and disease severity. Due to the arousal of a strong and specific immune 
response against the parasite, nearly two-thirds infected people become protected and may 
stay in an indeterminate stage of the infection characterized by low parasitemia level for 10 or 
even up to 40 years after the prime infection. The other one-third infected people, however, 
develop symptoms, entering the symptomatic chronic stage of infection typically character-
ized by cardiomyopathy.
The antigenic stimulation though persists all over the chronic stage. Then, the clinical out-
come depends on multiple factors like parasite persistence, the particular T. cruzi strain, the 
infective load and virulence factors, the route of infection and sidestepping the host immune 
response by the parasite, the strength of the immune response at any time, and of course, 
genetic predisposition [2]. In fact, the sustained parasite-host immunity interactions induce 
systemic inflammatory mediators’ upregulation and fibrosis, both crucially involved in 
myocardial tissue damage and the resulting disturbances in the cardiac conduction system, 
mainly affecting the autonomic ganglia, nerves, and the microvasculature.
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Unlike the study of the classical risk factors, research studies on how inflammatory status 
affects the development and determines the progression of cardiomyopathy have not yet 
identified or clinically validated relevant biomarkers [3]. Interestingly, secluded evidence 
suggests that the inflammatory status might be associated with increased morbidity and mor-
tality. Deepening our understanding of the pathophysiology of Chagas disease, it will make 
way to identifying new molecular targets for the design of CCC prophylactic vaccines and 
therapeutic drugs.
2. Cardiomyopathy genes
Dilated cardiomyopathies (DCM) are characteristically defined by the presence of left ventric-
ular dilatation, and contractile dysfunction [4]. Genetic mutations that involve genes encoding 
the cytoskeleton sarcomere, nuclear envelope proteins and others account for up to 35% of the 
total cases. Hypertrophic cardiomyopathies (HCM) and dilated (DCM) cardiomyopathies are 
heart muscle diseases related to genes variants encoding sarcomere proteins [5]. Among these 
proteins, the most common are the β-myosin heavy chain (MYH7) [6], the cardiac myosin-
binding protein C (MYPBC3) while the myosin light chain (MYL3) and the regulatory myosin 
light chain (MYL2) are rare [7]. Certain variants in sarcomere genes also cause DCM, albeit 
less frequently. Of note, variant location does not absolutely predict whether it will trigger 
HCM or DCM.
Heart failure associated with cardiomyopathies is often caused by mutations in sarcomeric 
genes, resulting in contractile dysfunction and cellular damage. This may stimulate the 
production of a robust proinflammatory response. Intriguingly, flow cytometry analysis 
revealed a significant increase in total macrophages and classically activated proinflamma-
tory (M1) macrophages in DCM hearts as compared with normal hearts. Serum cytokine 
analysis in dilated cardiomyopathy hearts showed a striking increase in interleukin IL-6 in 
rodents. Furthermore, RNA-seq analysis revealed the upregulation of inflammatory path-
ways in DCM hearts. Altogether, these data indicate a robust proinflammatory response in 
DCM hearts, likely in response to cellular damage triggered by an MYBPC3 mutation and the 
resultant contractile dysfunction [8]. In addition, other genes have been implicated in DCM, 
particularly the monocyte chemoattractant protein-1 gene polymorphism [9].
The epigenetic factors that contribute to myocarditis include consumption of alcohol or 
drugs, exposure to toxins, and metabolic and endocrine disturbances. The typically present-
ing symptoms are related to congestive heart failure, and can also include circulatory col-
lapse, arrhythmias, and thromboembolic events [10].
3. Anatomopathological findings of Chagas cardiomyopathy
Chagas disease is typified in the WHO classification within the group of specific diseases of 
the myocardium. Alternatively, the denomination of cardioneuropathy has been proposed 
to express the frequent and severe importance of the autonomic affectation and the conse-
quent dysautonomia associated with the functional and clinical alterations. The observed 
Chagas Cardiomyopathy: Role of Sustained Host-Parasite Interaction in Systemic Inflammatory…
http://dx.doi.org/10.5772/intechopen.77980
97
macroscopic alterations are: (a) cardiomegaly (more than 500 g weight) and (b) characteristic 
apical lesion associated with localized parietal thinning, rarely presenting as posterior basal 
or parietal, or an apex aneurysm. Some authors propose two characteristic morphological 
types of chronic chagasic cardiopathy: “type I” or concentric, is characterized by a predomi-
nance of left ventricular hypertrophy with little dilatation or none, and circumscribed closed 
apical lesion and “type II” or eccentric, characterized by a wide dilatation and opening of the 
apical zone and frequently associated with thrombosis. Pathological evolution can progress 
from the concentric to eccentric type (Figure 1).
4. Clinical expression of the acute phase of Chagas disease
The Chagas disease presents two phases [10]. The initial acute phase, lasting for about 
2 months after the infection and characterized by high parasitemia and parasite invasion to 
the tissues, is asymptomatic or shows mild unspecific symptoms. In this phase, symptomatic 
patients usually develop characteristic skin lesions or unilateral purplish swelling of the lids, 
Figure 1. Anatomopathological findings. Figure courtesy of Dr. José Milei. Panel 1, left. High-grade heart dilatation. 
Thining of the apical wall of the left ventricle (white arrow) and cavitary thrombus (yellow arrow). Panel 1, right. 
Schematic representation. Panel 2, left. Characteristic apical aneurysm. Panel 2, right. Schematic representation. Panels 
3–5. Histological features. Panels 3A and 3B. Microscopically, myocardial lesions consisted of a chronic inflammatory 
process with fibrotic scars and extensive mononuclear infiltrates. Panel 4. Immunostaining for T lymphocyte. Positive 
cells express CD45R0 antigen (brown); specialized myocardial cells have almost disappeared. Extensive mononuclear 
infiltrate, the majority of them being T lymphocytes. X20. Panel 5. Double immunostaining for the simultaneous 
demonstration of T lymphocytes (CD45RO) and macrophages (CD68). T lymphocytes (brown) in close contact with a 
macrophage (pinky cytoplasm). X1000.
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usually known as the Romana’s sign, and can present fever, headache, difficulty in breathing, 
lymphadenitis, vague myalgia, and abdominal or chest pain. In this phase too, immunosup-
pression, and the decreased inflammatory response result in increased parasite load in locally 
infected tissues upon generalized tissue invasion [11].
5. Clinical expression of the chronic phase of Chagas disease
To date, regardless the chronic phase be asymptomatic or symptomatic with cardiological 
alterations, the prognosis on the eventual development of heart disease in a given patient is 
not feasible.
5.1. Clinical asymptomatic expression of the chronic phase
The reason most patients with Chagas do not develop heart disease is uncertain. The first 
studies suggested that asymptomatic patients without clinical and cardiological alterations 
and the general population had a similar cardiovascular risk, but over time, epidemiological 
data suggest a higher risk than presumed.
Collectively, the studies highlight the importance of studying the early inflammatory param-
eters indicative of early cardiovascular damage, evaluating potential implication on morbid-
ity and mortality, and prognostic and therapeutic relevance.
5.2. Clinical symptomatic expression of the chronic phase
The clinical expression of the chronic phase usually manifests as alterations in the cardiac 
conduction system, mainly arrhythmogenesis and dysrhythmias derived from the fibrotic 
and atrophic lesions compromising the AV nodule, and the His bundle and branches, and 
autonomic dysfunction as well. Dysautonomia may affect blood pressure and cardiac fre-
quency, eventually leading to orthostatic hypotension, syncope, and heart failure. Myocardial 
alterations are associated with chronic inflammation, fibrous hypertrophy, fibrosis, myocy-
tolysis, tissue depletion of neurons, and vascular damage contributing to sudden death or 
heart failure. Some clinical features may result from upstream molecular mimicry and car-
dioactive autoantibodies production. Patients with chagasic cardiomyopathy produce anti-ß1 
and -ß2 adrenergic, and anti-M2 cholinergic autoantibodies in the heart. These autoantibod-
ies, originally directed against the parasite, would indistinctly recognize similar antigenic 
determinants in the host, a phenomena known as mimicry.
6. Factors that define blood inflammatory outcome in Chagas disease
The sustained systemic inflammatory burden may result from many host-parasite interac-
tions, whereby the interplay of the natural and adaptive immune host response with the para-
site will result in a varying degree of tissue damage, host aggression, and clinical outcome. 
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Then, the perpetuation of the Chagas disease inflammatory phenotype [10] is critical in 
understanding the complexity of the clinical outcome given that immunological homeostasis 
in chronically infected hosts could be spoiled by both parasite and host immune molecules 
and cells [10].
6.1. Factors that promote parasite evasion and persistence
The presence of the parasite [11] or its products like DNA, and other constitutive molecules in 
blood, myocardium, and the autonomic tissues lead to sustained immunological stimulation 
and T. cruzi evasive strategies. Today, the DNA amplification by polymerase chain reaction 
and other sensitive assays allow detecting parasites or their components in chronic symptom-
atic patients.
6.1.1. Parasitemia and sustained antigen stimulation
There is scarce evidence linking Chagas seropositivity with cardiovascular events in asymp-
tomatic patients [9]. The perpetuation of T. cruzi antigens in cardiac tissue and the immune-
mediated dysautonomia might be implicated in the cardiovascular pathogenesis [12] being 
responsible for the asymptomatic-to-the cardiac phenotype transition in Chagas disease. 
Different studies have shown the relevance of effector or memory CD4/CD8 lymphocytes 
and their effector cytokines not only in controlling parasite multiplication over the course 
of acute and chronic infection, but also participating in the pathogenesis of chronic Chagas 
disease [12]. The Th1 lymphocytes are critical in the control of Chagas disease during the 
acute stage unlike the chronic phase when they could be harmful. The adoptive transfer of 
T. cruzi-specific CD8+ T cells confers mice partial protection from T. cruzi inoculation [13], 
while cardiac damage may still develop. Conversely, the human being develops myocarditis 
in the presence of CD4+ and CD8+ T cells, and parasite components as well [14].
6.1.2. Cruzi virulence and immunomodulatory factors
Cruzi parasites cause pathology depending on factors like the parasite species and strains, the 
route of infection [15], and the host genetic background. Different parasite strains coexist in 
infected patients, and in natural reservoirs in domestic and peridomestic areas. The strain-
dependent immunomodulatory effects of the parasite might influence parasite-host interac-
tions [14]. Mucin-like sialic acid-acceptor glycoproteins and other parasite cell membrane 
products determine Cruzi virulence [15]. One of the hallmark parasite-derived molecules are 
the glycol-inositol-phospholipids (GIPLs) covering the parasite cell surface that alter the B cell 
compartment, work as TLR4 agonists, and mediate proinflammatory effects [16, 17]. In sum, 
T. cruzi virulence factors actively subvert the host immune system leading to chronic infection 
[18–21].
6.1.3. White adipose tissue is an immune active endocrine organ
Another survival strategy of Cruzi parasites is targeting the adipose tissue (AT) [22], both 
brown (BAT) and white (WAT), the largest endocrine organ in the body shaped by adipo-
cytes, fibroblasts, macrophages, and endothelial cells. The adipose tissue is involved in many 
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physiologic functions including energy homeostasis and immunity [23], and might warrant 
long-term parasite persistence by providing a safe reservoir to avoid the host-defense mecha-
nisms. Then, immune system suppression would result in parasite recrudescence and mul-
tiple tissue invasion [24]. Besides, the AT might be the major site for parasite reactivation as 
indicated by the finding of parasite-derived DNA in AT [25] in patients with CCC [25]. Likely, 
the AT serves as a parasite reservoir favoring opportunistic reinfection upon immunosup-
pression, as observed in chagasic transplanted or HIV patients, or those under immunosup-
pressive therapies [26]. As infection increases the level of TLR4 and TLR9, and of the mRNA 
of cytokines, chemokines, and of their receptors, the adipose tissue appears to be both a target 
and a sensor of parasitic infection even in the early, latent stage of T. cruzi infection. Recently, 
the T. cruzi was detected in the adipose tissue of chronically infected individuals [25].
6.2. Host-protective and pathogenic anti-T. cruzi immune-mediated-response
6.2.1. The innate immune system
Innate, nonspecific, immunity involves any pathogen-eliminating mechanism triggered 
promptly without memory requirement. The acute nonspecific inflammatory molecules serve 
not only as ‘gateway’ signals, generating conditions unfavorable for the invading agent, but 
they are also implicated in chronic inflammatory diseases. Chronic sustained inflammation 
actually contributes to cardiac hypertrophy.
6.2.1.1. Toll-like receptors agonists expressed by T. cruzi activate inflammatory pathways
Nonspecific immune system cells modify their functional repertoire (phagocytic activity, 
activation, antigenic presentation, migration, and adhesion) through pathogen-associated 
molecular pattern recognition receptors (PAMPs) like the toll-like receptors (TLRs), many of 
which can recognize several types of structurally unrelated PAMPs. These receptors trigger 
proinflammatory pathways’ activation interacting with their pathogen-derived ligands, and 
even with endogenous molecules, and releasing effector molecules like cytokines. This signal 
cascade triggers the expression of cytokine genes, where the type of TLRs bound determines 
the type of response.
Different T. cruzi-derived molecules belong to the PAMPs family and act as TLR agonists 
inducing the secretion of inflammatory cytokines, chemokines, and the production of nitric 
oxide (NO) by cells of the monocytic lineage. In this regard, the first evidence was the iden-
tification of the trypomastigotes-derived glycosylphosphatidylinositol (tGPI) that anchors 
mucin-like glycoproteins (tGPI-mucins), as a potent agonist of the human TLR2 [27] induc-
ing proinflammatory responses on cells which express normal levels of TLR2 and TLR4 
(Figure 2).
Another epimastigote-derived GPI family member, the glycoinositolphospholipid character-
ized by a lipid moiety, induced TLR4-mediated NF-κB activation. Many GIPLs freely anchor 
at the surface membrane of all the parasite life-cycle stage forms, whether infective metacyclic 
trypomastigotes or epimastigotes forms and have pleiotropic properties [28]. The variable 
lipid moiety composition of different GPI anchors determines the TLR type specificity for 
TLR2 (alkylacylglycerol) or TLR4 (dihydroceramide).
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6.2.1.2. Toll-like receptors and resistance to infection
Direct testing of the hypothesis that TLR triggering by PAMPs is crucial for host resistance 
to infection but is currently not possible due to unavailability of T. cruzi strains lacking the 
expression of any TLR agonist. Nevertheless, studying the course of infection in TLR-encoding 
genes-deficient mice, evaluating mortality, parasitemia, and several parameters of the innate 
and acquired immune responses have brought an additional understanding of the impact of 
impairing TLR-mediated recognition of T. cruzi in developing host susceptibility to the infec-
tion. In this regard, MyD88-deficient mice lacking the transducer of multiple TLR-signaling 
pathways first evidenced the crucial involvement of TLRs in host resistance to T. cruzi [29, 30].
6.2.1.3. Cardiac toll-like receptors increase in ischemia/reperfusion-induced cardiac 
hypertrophy
The development of cardiac hypertrophy involves TLR signaling so that MyD88 blockage 
attenuates cardiac hypertrophy and extracellular heat shock protein 70 (HSP70) induces car-
diomyocyte inflammation [31, 32].
6.2.2. The adaptive immune system
The immune-mediated-pathology (IMP) links to parasite persistence inducing protec-
tive effector and autoimmune response and has been a subject of debate in CCC for years. 
Immune effector cells along with autoantibodies participate in both protective and patho-
genic adaptive responses in CCC. Typically, histopathological examination in chronic myo-
carditis reveals inflammatory polymorphism with macrophages, eosinophils, mast cells, B 
and T lymphocytes, and granuloma cells, and a predominance of B cells and plasma cells 
in the epicardium and T cells in the myocardium, which progresses towards fibrosis. The 
mononuclear infiltrate and its mediators would be, at least partly, primarily responsible for 
myocardial damage [33].
Figure 2. T. cruzi molecules PAMPs members are TLR agonists. The variable lipid moiety composition of different GPI 
determines whether their recognition is mediated by TLR2 (alkylacylglycerol) or TLR4 (dihydroceramide). TLR4 agonist 
triggers powerful proinflammatory molecules release. FL: Phagolysosome; GPI: Glycosylphosphatidylinositol; tGPI: 
Trypomastigotes-derived glycosylphosphatidylinositol; eGPI epimastigote-derived glycosylphosphatidylinositol, HSP: 
Heat shock protein.
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6.2.2.1. Autoimmunity
At first post-infectious autoimmune myocarditis was proposed to reasonably explain the mis-
match between myocardial areas showing parasite invasion and those with myocardial dam-
age revealed by pathology examination that hampered reliably establishing Chagas disease 
pathogenesis.
• Cardiac epitopes share amino acid sequences with T. cruzi epitopes.
• The transfer of lymphocytes to syngeneic recipients produces inflammatory lesions in car-
diac and nervous tissue.
• Chronic chagasic patients have autoantibodies in the bloodstream.
• Plasma cells obtained from murine myocardial lesions release anti-cardiac antibodies.
• T-lymphocytes obtained from human biopsies show cardiac muscle reactivity.
6.2.2.1.1. Evidence derived from the autoreactive immune response
While activation of autoreactive clones (possibly by polyclonal activation) occurs during the 
acute primary infection phase, autoantibodies appear to be generated during both the acute 
and chronic phases of the disease, likely perpetuated due to myocardial reactivity regardless 
of the etiologic agent. Both humoral and cellular cardiac autoimmunity might develop upon 
acute T. cruzi infection in the genetically susceptible host [34]. Another hypothesis sustained that 
autoimmunity develops only after sustained low-level stimulation of self-reactive cells over the 
chronic phase. Altogether, self-reactivity was initially proposed as a mechanism of tissue damage.
Many publications have mentioned the presence of cardiac tissue-parasite cross-reactivity. 
T. cruzi may induce antibodies and T cells also reactive to host antigens causing autoimmune 
reactions.
Certain antigens might induce nonspecific polyclonal activation, expanding clones that were 
in the anergic state as the polyclonal B cell activation associated with hypergammaglobu-
linemia and delayed specific humoral immunity reported in T. cruzi experimental infection 
in mice [35].
All in all, self-reactivity is accepted in Chagas disease though only subsidiarily contributing to 
myocardial tissue damage and deterioration as argued for the presence of autoantibodies and 
lymphocytes at the site of the lesion. Actually, immunosuppression not only does not cause 
improvement but rather aggravation of the course of the disease. Indeed, was self-reactivity 
relevant to injury, immunosuppression should be beneficial. Immunosuppression during 
acute infection reduces tissue inflammation while the parasite load increases in the infected 
tissues in mice. However, immunosuppression results in a generalized tissue invasion aggra-
vating the disease. In chronically infected individuals, parasitemia is undetectable but any 
induced or acquired immunosuppression condition including pharmacological treatments, 
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AIDS, a transplant, an autoimmune disease, leukemia or pregnancy, may trigger reactiva-
tion. When immunosuppression occurs during the chronic stage, skeletal and cardiac muscle 
inflammation increases, allegedly explaining why a subset of patients presenting an insuf-
ficient or suboptimal immune response develop heart disease [36].
6.2.2.1.2. Evidence derived from molecular mimicry and the formation of cardioactive 
autoantibodies
Cardioactive substances from sera from chagasic patients. Subsequently they were character-
ized as antibodies with specificity towards the cardiac β-adrenergic receptors that acting as 
partial agonists  increased mechanical tension and sinus beating frecuency in chagasic patients. 
The Cardiology Service of the Ramos Mejía Hospital contributed to the characterization of 
the anti-cardiac receptor reactions, and the results indicated that self-reactivity of this kind 
was caused by parasite epitopes with low affinity for cardiac receptors, later proved by the 
identification of anti-T. cruzi P ribosomal proteins in chagasic individuals. In in vitro or ex vivo 
experiments, IgG-enriched serum fractions obtained from chagasic patients modify baseline 
heart beating frequency in cultured cardiomyocytes, increase cardiac inotropism, and trigger 
atrioventricular blockage in isolated hearts. Rabbits immunized with the major immunogenic 
region of β-adrenergic receptors develop cardiomyopathies and malignant arrhythmias, and 
cardioactive antibodies have also been observed in other pathologies. Patients with ethiologi-
cally different chronic heart diseases like the idiopathic dilated cardiomyopathy or present-
ing primary electrical alterations produce chagasic IgG-like enriched fractions with antibody 
activity. Circulating autoantibodies to cardiac beta-adrenergic and muscarinic receptors may 
affect cardiac function in chagasic patients. The prevalence of anti-autonomic receptors anti-
bodies was higher in patients with chronic chagasic heart disease and other forms of heart 
disease than in the healthy counterparts [36].
6.2.2.2. Immune origin of the disease and the localized inflammatory response
The ‘tissue load of parasites’ is associated with the ‘severity of the lesion’ and might predict 
not only the characteristics of the immune response in the acute or chronic (reactivation by 
immunosuppression) stages of the disease of the disease but also of the localized inflammatory 
response. Accordingly, tissue specificity would result from the local ‘parasites persistence’ in 
the site of inflammation. Whole, fractionated, or recombinant parasites immunization triggers 
inflammatory lesions and electrocardiographic alterations. The spectrum of clinical presenta-
tions might result from both the efficacy of the immune response during the acute stage and 
the parasite strain involved. Individuals infected with less virulent strains and immunocom-
petent hosts should become asymptomatic over the chronic stage (Figure 3). The immune 
response so results from the net balance of the T. cruzi strain immunogenic potency and the 
regulatory T cells and effector lymphocyte subpopulation Th1/Th17 during the infection. The 
IL-17 produced during experimental T. cruzi infection regulates Th1 cells differentiation and 
parasite-induced myocarditis. A low regulatory T cell activity and the frequency of IL-17-
producing T cells correlate with CCC severity [37], not precluding a minor participation of the 
self-reactive immune reactions in producing injury.
Induced immunosuppression fails to cause relevant autoimmune-mediated damage for it 
aggravates rather than ameliorates the disease. Adoptive lymphocytes transfer to syngeneic 
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recipients produces inflammation indicating that the T-response can effectively control the 
disease. The cellular immune response is critical in controlling T. cruzi infection, and the 
developed vaccine so far exacerbates damage and progression of the disease. Then, the vac-
cine either failed in enhancing the adequate response and/or its design requires further adjust-
ing the epitopes. Of note, despite cellular control the infection, immune response persistence 
and cardiac infiltrated cells may cause injury. Finally, the contribution of autoantibodies is 
complex as it is likely involved in further enhancing cardiovascular damage.
7. Suppressor of cytokine signaling proteins, immune regulation, 
and dilated cardiomyopathy
Cell-cell signaling is an essential hallmark of multicellular organisms for communicating 
different cell populations [38] and is particularly crucial for the immune system function. 
The ‘suppressor of cytokine signaling’ (SOCS) plays a critical role in the regulation of all 
Figure 3. Possible mechanisms involved in the immunopathogenesis of Chagas disease. Although the immune system 
protects man from massive infection, he is unable to completely eliminate all parasites. (A) The humoral protective and 
immunopathogenic immune response to T. cruzi has been intensely studied. Although many questions remain, the 
antibody response is always present in infected individuals and many of the antibodies have a protective capacity. Several 
aspects are related to the presence of autoreactive antibodies in chagasic patients and in experimental chagasic models. 
The presence of similarities between the epitopes of the parasite and cardiac tissue leads to the expansion of autoreactive 
clones. Some authors argue that some autoantibodies should be due to the existence of polyclonal activation. Other 
autoantibodies may be the result of the autoantigen release of damaged tissue (epitopes dispersion epiphenomenon). 
(B) Th1 lymphocytes have great relevance in the control of the disease. The importance of the T-dependent response is 
evidenced by the observations recorded in immunosuppressed patients in whom the disease worsens. In vitro studies 
would indicate that the NK cell-mediated immune response (ADCC and natural cytotoxicity) could participate in 
the in vivo response. According to some authors the antigenic persistence would be the main mechanism inducing 
the inflammatory immune response in the chronic stage and IL17 seems to be involved in CCC. This interpretation 
postulates that the sustained activation of the immunoinflammatory response is the main cause of tissue damage.
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crossroads of the cytokine-induced pathogenesis of dilated cardiomyopathy. The SOCS3 
transgene induces Th2 responses, and SOCS3 gene deletion did not enhance Th1 polarization 
as expected but induced a negative regulator of the Treg subset with increased IL-10 and 
TGFβ production in mice [39, 41]. Not only SOCS3 is essential for G-CSF, IL-6, LIF, and leptin 
signaling, but is also an indirect regulator of IFNγ signaling and a negative regulator of IL-23 
signaling, inducing IL-17-secreting T cells (Th17) polarization (Table 1).
The SOCS3 pathways are important, altering cardiac physiology by affecting molecular targets 
associated with myocardial changes implicated in structural pathologies. The SOCS3 proteins 
regulate specific cytokine pathways related to cardiac growth and enlargement and seem to be 
consistent with their roles critical regulators of hypertrophy, contractile dysfunction, and ven-
tricular arrhythmias. They were, as their name suggests, first described as cytokine signaling 
inhibitors as observed for the Janus kinase/Signal Transducer and Activator of Transcription/
Suppressor of Cytokine Signaling (JAK/STAT/SOCS) signaling pathway (JSS-SP). The remodeling 
by cytokine receptor signaling mediated by the JSS-SP provides a morphological basis explaining 
the pathogenesis of myocardial hypertrophy, fibrosis, and inflammation [41] in CCC. The inflam-
matory markers TNFα, and IL1-β represent potential targets in cardioprotection and therapy [42].
The SOCS3 protein is a key negative-feedback regulator of the gp130 receptor involved in 
signaling pertaining cardiac hypertrophy and survival. Activation of the gp130 without 
SOCS3 regulation leads to cardiac hypertrophy, in line with their roles as negative regula-
tors of cardiac growth. Also, SOCS3 regulation on cardiac gp130 signaling participates in the 
pathogenesis of contractile dysfunction and ventricular arrhythmias. Consistently, human 
CCC is characterized by segmental left ventricular wall motion abnormalities (WMA), mainly 
in the early stages of the disease.
The failure of the SOCS3 protein, also a major negative regulator of both leptin, and insulin 
signaling, might participate in the pathogenesis of obesity, and associated metabolic abnor-
malities as found for diet-induced and genetic obesity, systemic inflammatory burden, and 
SOCS 
type
Factor Effect References
SOCS3 G-CSF Hematopoietic neutrophilia/inflammatory conditions Chen et al. [35]
IL-23 (↑IL17), 
(↑IFN-γ)
Enhance Th1 and Th17 polarization Chen et al. [35]
Leptin Resistance to diet-induced obesity Yang et al. [39]
IL-6, (+IL-27) Reduced CD8+ T cell proliferation Yang et al. [39]
TNF-γ, IL1β Hypertrophy, fibrosis and inflammation Liongue et al. [33]
Global action • Critical role in regulation of cytokine signaling
• Control of hyperproduction of IL-10 and TGFβ
• Promote Th2 response
• Indirect sustained Th1 activity
Kinjyo et al. [34], Chen 
et al. [35]
Table 1. Main action of SOCS3 as a critical regulator.
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hyperlipidemia. In sum, the SOCS3 may be critically negative regulators of inflammation, 
cardiac hypertrophy, contractile dysfunction, and ventricular arrhythmias. However, our 
understanding of the origins of the individual pathway components and their assembly into 
a functional pathway has remained limited.
8. Long-lasting systemic inflammatory burden and clinical Chagas 
progression
The immune-inflammatory response plays a key role in cardiovascular damage [40, 41], and 
T. cruzi-derived molecules may sustain the TLR-mediated innate immune response inducing 
inflammatory cytokines and chemokines secretion. The adaptive immune response to Chagas 
antigens may protect the host from secondary reinfection, though damaging the CV system 
due to inflammation, and the associated connective repair (fibrosis).
Crossroads between “natural, and specific immunity effector cells and molecules” and “para-
site persistence strategies in blood, adipose tissue, the heart, and other infected tissues” seem 
to contribute to cardiovascular risk. Tissue damage induces inflammatory reactions. Immune-
activated pathways are the main contributors to systemic inflammation in human CCC by 
active crosstalk between different CVRFs, metabolic and immune-mediated innate and adap-
tive host-parasite interactions. The contribution of natural and specific immunity against 
Chagas antigens enhance systemic inflammatory burden (SIB). Certainly, the immune system 
is not the only source of inflammatory molecules, but other tissues also contribute to enhanc-
ing systemic inflammatory burden as the WAT which releases inflammatory cytokines.
In a recent study, the levels of IL1β, IL6, IL10, TGFβ, IL12, IL17, TNFα, and serum IFNα were 
different in either chronic asymptomatic or cardiac chagasic patients compared with healthy 
controls. The asymptomatic patients had a higher plasma TNFα concentration (eightfold) and 
IL10, and lower IFNα than in normal controls, suggesting a process of immune regulation. 
Neither the interaction with traditional CVRFs and their contribution to CVR nor control-
matching for age, sex, weight, or BMI were considered in this study. The advent of noninva-
sive imaging techniques allows studying the relationship between inflammatory markers in 
subclinical atherosclerosis development. The association of many systemic diseases with an 
increase in the prevalence of cardiovascular diseases involves immunoinflammatory media-
tors related to chronic inflammation and cannot be explained by the classic CVRFs. Unlike 
the classical CVRFs like the lipid profile, the approaches based on the contribution of the 
inflammatory milieu to cardiovascular disease development have not yet allowed identify-
ing clinically validated biomarkers regardless the evidence suggesting their association with 
increased morbidity, and mortality except CRP [43].
Scientific research is encouraged to delve into the important role suggested for the inflammatory 
response in the metabolism and control of the atherogenic potential [44]. Hypercholesterolemia 
and inflammation are certainly considered contributive partners in atherosclerosis.
Only lipid-related indicators like LDL- and HDL-cholesterol fractions, and triglycerides 
are currently recommended in predicting cardiovascular risk. Paradoxically, plasma total 
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cholesterol level is accepted as a marker of relative CVR, though more than 50% of all cardio-
vascular events can occur in individuals with concentrations below the accepted normal total 
cholesterol level [56].
With a complete understanding of atherogenesis, the atherothrombotic markers, and the 
already mentioned inflammatory markers [45] are potentially available for CVR estimation.
Recent data suggest that the measurement of related inflammatory markers may improve 
cardiovascular risk assessment. Certain markers being evaluated include a group termed as 
“cellular” cytokines (e.g., IL1, IL2, IL12p40, IL15, IL17, TNF, IFN, and IFN), and “humoral” 
cytokines (e.g.IL4, IL5, IL6, IL10, and IL13), growth factors and angiogenic [e.g., EGF, VEGF, 
FGF, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage-colony-stimu-
lating factor (GM-CSF)], and chemokines [e.g. CCL2 (MCP1), CCL3 (MIP1), CCL11 (Eotaxin), 
and CXCL8 (IL8)]. The role of some of them in cardiovascular pathogenesis is described 
below.
8.1. Soluble ICAM1
Inflammatory stimuli trigger a dramatic increase in ICAM1 expression on the vascular sur-
face. Later on, inflammatory cytokines induce the endothelial expression of VCAM1 which, 
like ICAM1, interacts with leukocyte integrins promoting the firm adhesion of leukocytes to 
the surface of the endothelial cells. After proteolytic cleavage, the endothelial ICAM1 mol-
ecules can be released into the circulation as soluble molecules (ICAM1s), the level of which 
correlates with CVRFs like smoking, hypertension, hypercholesterolemia, and hypertriglyc-
eridemia and with acute phase reactants like the PCR, and increases in patients with coronary 
disease. The circulating level of the soluble forms of ICAM-1, VCAM-1, selectin, and CD44 are 
remarkably high during the acute T. cruzi infection, while the soluble forms of VCAM-1 and 
P-selectin increase in chronic infection [46–52]. As inflammation markers, the soluble forms of 
ICAM-1 might be notably higher in patients with DCM [53–55].
8.2. Chemotactic monocyte-1 protein
An important early step in atherosclerosis is the adhesion of monocytes to activated endothelial 
cells. The endothelium produces several molecules critical in the proatherogenic events like the 
endothelium-released MCP1 which contributes to increased monocyte recruitment, and activa-
tion of nuclear factor kappa B (NF-kB) involved in the transcription of many functional genes 
in the inflammatory process [64]. Recently, CCL2/MCP-1 has emerged as a critical factor in 
infectious and autoimmune myocarditis, is largely produced in T. cruzi-loaded mice hearts, and 
it promotes macrophages infiltration and parasite destruction. T. cruzi-infected CCL2(−/−) mice 
developed higher parasitemia, dying prematurely, and showed increased levels of TNF, IFN-
gamma, and IL-10 in plasma, clinical signs of systemic inflammatory response. Cardiac density 
of amastigote nests was associated with leukocytes infiltrates. Other studies demonstrated 
that CCL2 contributes to the reduction of parasite growth by controlling the distribution, cel-
lular composition, and the status of inflammatory infiltrates in acute T. cruzi infection [21]. 
More recent evidence shows that polymorphisms involved key molecules related to innate 
immunity, and that cell migration plays a critical role in genetic susceptibility to CCC [56–58].
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8.3. Interleukin 10
Within the group of the so-called anti-inflammatory cytokines, the human IL10 is associated 
with an anti-atherogenic action reducing inflammation. Cytokine knockout of the Th1 inhibi-
tor IL10 increase vascular lesions [59]. IL10 has strong regulatory properties on macrophages 
and T cells, and negatively regulates many cellular processes involved in atherosclerotic 
plaque development and stability.
A recent study revealed comparable serum cytokine levels in cardiac chagasic and asymptom-
atic patients though IL10 level was higher, and IFNγ level was lower in the former suggesting 
a greater regulatory activity in cardiac patients. Presumably, the IL10 level is ineffective to 
restore homeostasis. Likewise, circulating IL10 increases in patients with DCM.
8.4. Transforming growth factor beta (TGFβ)
The transforming growth factor beta is produced by different cell types including adipo-
cytes, macrophages, endothelial cells, smooth muscle cells, platelets, and regulatory T cells. 
The TGFβ1 factor stimulates PAI-1 release and suppresses leptin release from the human 
adipose tissue. It inhibits atherogenesis modulating T-lymphocyte activity rather than 
modulating the prothrombotic and fibrinogenic activity, as confirmed in TGF II receptor 
type-KO models. It is also involved in regulating host tissue fibrosis. The oral administration 
of GW788388, a novel kinase inhibitor type associated with TGFß I and II receptors, remark-
ably increased cardiac cells’ survival time and decreased cardiac fibrosis, offering a potential 
alternative to the current asymptomatic Chagas treatment. However, the cost-benefit bal-
ance is uncertain since circulating TGFβ modulates the pathogenic effector immune response 
avoiding immune damage but exacerbating fibrosis. Recent studies indicate that the deep 
alterations induced by circulating TGFβ increase in patients with DCM with or without car-
diac fibrosis [60–62].
8.5. Interleukin-17A
The interleukin-17A cytokine released by Th17 cells is elevated in plasma in atherogenesis mice 
models. Increased serum levels of IL17 and IFNγ are found in patients with coronary athero-
sclerosis. The proatherogenicity of IL17A results from the monocytes/macrophages recruit-
ment into the aortic wall [63]. The differentiation of Th17 depends on IL23 and IL6 released 
by myeloid dendritic cells, IL1, IL6, and IL21 derived from macrophages and T lymphocytes 
[64]. In humans, TGFα acts as a negative regulator of IL17. For years, Chagas-associated car-
diac damage has been attributed to immunological dysregulation, including an imbalance 
between pro- and anti-inflammatory cytokines, Th1-Th2 immune deflection, and regulatory 
T cell activity. Recently, IL17 produced during experimental T. cruzi infection regulated Th1 
differentiation, and parasite-induced myocarditis. The decrease in IL10 and IL17 cytokines’ 
production in association with high levels of IFNγ, and TNFα correlates with the severity of 
human chagasic cardiomyopathy. This immunological imbalance might be causally related 
to a poor suppressor activity of the regulating T cells controlling myocardial inflammation. 
Finally, the derived IL17A-fibroblast and the derived -GM-CSF-macrophage axis are potential 
targets for the treatment of DCM and related inflammatory cardiac disorders [64].
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8.6. C-reactive protein
The CRP marker level is used as a predictor of future cardiovascular events, being a good esti-
mator of mortality risk in different contexts, particularly in metabolic syndrome in the general 
population. It has also been suggested as a direct stimulator of plaque formation decreasing 
endothelial nitric oxide synthase (eNOS) activity [65], and implicated in other deleterious 
effects. In vitro studies provide evidence of the proatherogenic direct effects of CRP as found 
in endothelial dysfunction, Also, an increase CRP serum level in chagasic patients has been 
associated with a greater progression towards heart failure. High hs-CRP level is associated 
with a higher incidence of the long-term combined endpoint of all-cause mortality and hos-
pitalization in patients with DCM. Besides, oxidative stress molecules and hs-CRP are both 
associated with heart failure and damage severity in patients with DCM [66, 67].
8.7. Tumor necrosis factor alpha (TNFα)
The pleiotropic TNFα cytokine is one of the most potent mediators of inflammation. It is 
associated with an increased CVR. It can induce proatherogenic lipid alterations, including 
increased LDL-cholesterol and HDL-cholesterol [68] and promote hypercoagulability induc-
ing tissue factor (TF) expression in endothelial tissue and suppressing anticoagulant activity 
through activated thrombomodulin-activated protein C [69]. It also induces endothelial dys-
function through decreasing nitric oxide and regulating adhesion molecules, an early critical 
step in atherogenesis. Several investigations in animal and human models provide convinc-
ing evidence on the action of TNFα as one of the major regulators of vascular homeostasis. 
Blocking of TNFα results in a significant decrease in Lp (a), homocysteine levels and increases 
in Apo AI, triglycerides, and Apo B concentration. The prolonged use of TNFα blocking agents 
interferes with proatherogenic action, reducing the incidence of cardiovascular events. Taken 
together these studies confirm a critical role of TNFα at the prothrombotic, proinflammatory 
and metabolic level. An association between TNFα levels with heart failure was observed in 
chagasic patients. Autopsies specimens confirmed the presence of cardiac inflammatory cell 
infiltrates showing a Th1 cytokines pattern. Chronic asymptomatic chagasic patients have 
TNFα plasma concentrations roughly eightfold higher than healthy controls, and TNFα may 
play a role in progression to heart failure, The increased level of TNFα might also be related to 
disease severity in chronic Chagas disease as found in patients with DCM. Interestingly TNFα 
blockage aggravates experimental CCC [70, 73].
8.8. Interleukin-1 (IL-1)
The IL-1 interleukin is a crucial proinflammatory mediator in acute and chronic inflammation, 
and also a powerful innate immune response inducer. It induces the synthesis and expression 
of several hundreds of secondary inflammatory mediators in different diseases [74, 75]. The 
inflammatory response is associated with the expression of numerous cytokines [interferon 
gamma, interferon alpha, tumor necrosis factor (TNF), and interleukin-3 (IL-3)], which stimu-
late xanthine oxidoreductase (XOR). The main circulating form of IL-1 is the IL-1β, initially 
synthesized as the pro IL-1β a precursor which is activated by caspase-1 cleavage in the set-
ting of a macromolecular structure known as the inflammasome [71]. Many potential triggers 
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of the inflammasome have been identified, including microbial agents, ischemia, damaged 
cells, cholesterol crystals, and TLRs ligands such as danger-associated molecular patterns 
(DAMPs) or pathogen-associated molecular patterns (PAMPs). The IL-1 molecule has been 
associated with endothelial dysfunction, hypertension, heart failure, and diabetes [75]. Recent 
studies indicate that XOR and XO serum levels are considerably increased in both cardiac 
and asymptomatic patients following T. cruzi invasion. Serum levels of IL-1β could be used 
in predicting the long-term outcome of patients affected by idiopathic DCM [71, 76]. Cardiac 
fibrosis and heart failure progression in inflammatory dilated DCM might be related to the 
myeloid differentiation factor-88/IL-1β signaling pathway [72, 77].
8.9. Interleukin-6
IL-6 provides a link between innate and adaptive immunity through the regulation of leuko-
cyte activation, differentiation, and proliferation. During the acute and chronic inflammatory 
response, macrophages release TNFα in the presence of a variety of stimuli including athero-
genic factors. In the macrophages, TNFα triggers the release of TNFα, and of more IL1B, which 
stimulates endothelial cells to produce IL6 and IL8. To date, both the scientific outcome of exper-
imental studies, and the abundant clinical evidence in atherosclerosis indicate that low-intensity 
sustained inflammation plays a key role in atherosclerotic plaque formation, progression, and 
destabilization leading to clinical endpoints like myocardial infarction, sudden death, or stroke. 
The underlying mechanisms are still unclear, despite the intense research over the past two 
decades. Both IL6 and its signaling events contribute to atherosclerotic plaque development and 
destabilization. Increased levels of IL6 [78, 79] and CRP, an accepted CVRF, can also contrib-
ute to atherosclerosis and arterial thrombosis by activating tissue factor production, increasing 
adhesiveness of endothelial cells, fibrinogen and factor VIII and stimulating platelet production, 
and aggregation [91]. In addition, smooth muscle cells (SMC) also produce abundant IL-6. Other 
inflammatory factors generated by adipocytes like IL6, CRP, and TNFα are also implicated in 
the pathophysiology of the metabolic syndrome. The polymorphism of IL6 genes correlates with 
the severity of coronary artery disease, and with myocardial infarction risk [80, 81], but not with 
carotid atherosclerosis, which seems to be independent, These findings clearly suggest a strong 
association between IL6 levels, atherosclerosis, and risk of cardiovascular death. Produced locally 
IL6 in the endothelial vasculature and by SMC, IL6 induces ROS production, proliferation, and 
SMC migration. IL6 is an important autocrine and/or paracrine regulator of SMC proliferation 
and migration, critical steps in atherosclerosis progression. Besides, circulating IL-6 levels (in 
parallel with an increase in circulating CRP) increase with progression to heart failure in Chagas 
disease. These observations agree with the polymorphisms analyzed in patients with idiopathic 
dilated cardiomyopathy (IDCM) that relates to TNF, IL-6, and CRP profile. A recent study shows 
that a rough increase in serum IL-6 is incidental with chronic IDCM [82].
9. Conclusion
Search results illustrated that immune-activated pathways are the main contributors to sys-
temic inflammation in human CCC due an interplay and active crosstalk between different 
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traditional risk factors, mainly metabolic and inflammatory factors derived from immune-
mediated host-parasite interactions, both innate and adaptive.
Tissue damage induces inflammatory reactions leading to dilated cardiomyopathy in geneti-
cally predisposed persons. The DCM represents an essential hallmark of CCC. Evidence 
suggests that the pathway of inflammation in DCM culminates in altered concentrations of 
various markers in peripheral blood, including oxidative stress molecules and markers of 
vascular and systemic inflammation. These scenarios necessarily require a means of commu-
nicating between different cell populations. Crossroads between “natural and specific immu-
nity effector cells and molecules” and “parasite persistence strategies in blood, adipose tissue 
and heart and other infected tissue” would appear to contribute to cardiovascular risk. The 
Suppressor of Cytokine Signaling (SOCS) plays a critical role in the regulation of all crossroads 
of cytokine inflammatory network that induced pathogenesis of dilated cardiomyopathy and 
seems to play a critical role as negative regulators of inflammation, hypertrophy, contractile 
dysfunction and ventricular arrhythmias. However, our understanding of the origins of the 
individual pathway components and crossroads and their assembly into a functional pathway 
is limited so far. Unlike classical risk factors, approaches based on inflammatory status needs 
clinically validated biomarkers and its contribution to the development of cardiomyopathy in 
chagasic and IDCM needs additional studies, even when there is strong evidence suggesting 
increased morbidity and mortality associated with the systemic inflammatory burden and 
inflammatory cardiomyopathy.
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